ProbioTech USA

ProbioTech USA is an IND-stage biopharmaceutical company headquartered in Princeton, New Jersey, specializing in the development of next-generation prescription therapeutics. The company creates novel treatments by combining clinically validated bacterial strains with prebiotic antioxidants, utilizing a patented dual-phase, dual-compartment delivery technology. This proprietary system is designed to ensure the controlled release of active ingredients at the specific site of action, effectively addressing microbiome disruption. The company maintains an intellectual property portfolio with granted patents in the United States, Europe, and Australia, and is currently advancing several clinical programs to provide targeted, safe, and effective interventions.

These therapies are primarily designed to address high-need conditions within the gastrointestinal, oncology, and women's health sectors, including recurrent Clostridioides difficile infection and ulcerative colitis. By targeting the root cause of these inflammatory and immune-driven conditions through the restoration of microbial balance and the reduction of oxidative damage, ProbioTech USA aims to offer a precise, prescription-based path to improved patient health. The company is actively working through the regulatory approval processes to bring these innovative biotherapeutics to the global prescription market.